Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

FIH Study of the GEMINUS TAVI System in Patients With Severe Symptomatic Aortic Stenosis

NCT: NCT05909748 · RECRUITING

NCT IDNCT05909748
StatusRECRUITING
Start Date2023-05-21
Completion2030-04
SponsorValve Medical (INDUSTRY)
First posted
Last updated

Brief Summary

The main objective of this study is to evaluate the feasibility and safety of the GEMINUS system in patients with severe symptomatic aortic stenosis. This is a prospective, open label, multicentre, single arm, first in human clinical study. Clinical follow up for all patients will be performed at 30 days, 6 months, 1, 2, 3, 4 and 5 years post-implantation

Frequently Asked Questions

What is FIH Study of the GEMINUS TAVI System in Patients With Severe Symptomatic Aortic Stenosis?

FIH Study of the GEMINUS TAVI System in Patients With Severe Symptomatic Aortic Stenosis is a clinical trial registered under NCT05909748. Current status: RECRUITING.

What is the status of NCT05909748?

The current status of NCT05909748 (FIH Study of the GEMINUS TAVI System in Patients With Severe Symptomatic Aortic Stenosis) is: RECRUITING.

When did FIH Study of the GEMINUS TAVI System in Patients With Severe Symptomatic Aortic Stenosis start?

FIH Study of the GEMINUS TAVI System in Patients With Severe Symptomatic Aortic Stenosis started on 2023-05-21.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.